Metformin: A Diabetes Drug with Potential Anti-Aging Properties, Researchers Suggest
Metformin, a medication widely used since the 1950s to treat type 2 diabetes, is being investigated for its potential to transform human health by slowing biological aging. In a recent review published in the journal Aging, researchers describe metformin as a potential "wonder drug" but emphasize that more research is necessary to fully understand its benefits and mechanisms. Metformin is recognized as a first-line treatment for type 2 diabetes and is included in the World Health Organization's list of Essential Medicines. Despite its long history of use, recent studies suggest that metformin's capabilities extend beyond blood glucose regulation. The review, led by genomics researcher Jarra Manneh from Hamad Bin Khalifa University in Qatar, highlights metformin's role in activating AMP-activated protein kinase (AMPK), an enzyme that not only aids in lowering blood glucose levels but also influences various cellular processes. These processes include inhibiting the mTOR protein kinase, which enhances autophagy—the recycling of damaged cellular components—reducing oxidative stress, and improving insulin sensitivity. Collectively, these actions may contribute to slowing cellular aging, potentially leading to increased longevity in animal models. However, the exact pathways through which metformin may affect aging in humans remain largely theoretical. Research has shown that elevated AMPK levels can extend the lifespan of certain organisms, while the absence of this enzyme can shorten lifespan in others. Additionally, metformin may induce epigenetic changes related to metabolism and inflammation by stabilizing the enzyme ten-eleven translocation 2 (TET2). This stabilization appears to reduce abnormal DNA methylation patterns, which are associated with genomic instability during aging. A notable study from 2022 indicated that metformin use in type 2 diabetes patients correlated with epigenetic markers of slower aging, showing a difference of approximately 2.7 to 3.4 years in biological aging compared to non-users. However, this study involved a small sample size of just 32 patients, and causation cannot be firmly established. Metformin's potential benefits may also extend to the gut microbiome, where it is thought to induce changes that reduce inflammation and enhance metabolic health. An experiment involving mice on a high-fat diet revealed that metformin treatment was linked to reduced tumor growth, likely mediated by alterations in gut bacteria. Despite the promising findings, researchers caution that definitive evidence of metformin's effects on human longevity is still lacking, as most studies conducted so far have been observational or focused on specific diseases rather than healthy populations. The review notes that many existing studies have varied endpoints, complicating the assessment of metformin's impact on overall healthspan versus specific disease outcomes. Looking ahead, the upcoming Targeting Aging with Metformin (TAME) trial aims to provide clearer insights by examining the drug's effects in a larger cohort of 3,000 participants across 14 research institutions over six years. If successful, these trials could substantiate the numerous promising signals observed in earlier research. Until such evidence is available, the full potential of metformin as a means of mitigating the effects of aging remains to be realized. The researchers conclude that further investigations, particularly randomized clinical trials in non-diabetic populations, are essential to explore metformin's epigenetic and microbiome-mediated effects and to develop predictive biomarkers of aging responsive to the drug. By integrating data from clinical, molecular, and population studies, metformin could redefine the boundaries of healthy aging.




